← All trials
NCT04731025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 27, 2021
- Primary completion
- Jul 27, 2024
- Completion date
- Jul 27, 2024
- First posted
- Jan 29, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 1003
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of Southern DenmarkCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenSponsor investigator
- Region SyddanmarkCollaborator
- Sydvestjysk HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.